Tyra Biosciences (NASDAQ:TYRA) Announces Earnings Results

Tyra Biosciences (NASDAQ:TYRA) released its quarterly earnings results on Tuesday. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.07), FiscalAI reports.

Tyra Biosciences Stock Down 5.8%

TYRA stock opened at $21.00 on Wednesday. Tyra Biosciences has a twelve month low of $13.83 and a twelve month high of $40.65. The company has a market cap of $1.25 billion, a PE ratio of -8.75 and a beta of 0.65. The business’s 50-day simple moving average is $22.04 and its 200 day simple moving average is $29.54.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on TYRA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Thursday, October 15th. Raymond James Financial restated a “strong-buy” rating and issued a $50.00 price objective on shares of Tyra Biosciences in a research note on Tuesday, October 6th. Jefferies Financial Group reaffirmed a “buy” rating and set a $42.00 target price on shares of Tyra Biosciences in a research report on Wednesday, August 5th. Piper Sandler reiterated an “overweight” rating and set a $56.00 target price on shares of Tyra Biosciences in a research note on Tuesday, September 8th. Finally, HC Wainwright cut their target price on shares of Tyra Biosciences from $30.00 to $29.00 and set a “buy” rating for the company in a research note on Tuesday, September 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Tyra Biosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $47.20.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for genetically defined diseases. Its research focuses on small-molecule therapies that target the fibroblast growth factor receptor (FGFR) family and related pathways, using a drug-discovery approach designed to address resistance and selectivity challenges. The company’s pipeline includes TYRA-300, a selective FGFR3 inhibitor being studied for conditions including achondroplasia and urothelial cancer, and TYRA-200, an FGFR inhibitor being developed for certain cancers.